Related Experiment Video
Updated: Jan 4, 2026
11:07
Biodegradable Magnesium Stent Treatment of Saccular Aneurysms in a Rat Model - Introduction of the Surgical Technique
Published on: October 1, 2017
11.5K
Second-Generation Drug-Eluting Resorbable Magnesium Scaffold: Review of the Clinical Evidence
Yuichi Ozaki1, Hector M Garcia-Garcia1, Evan Shlofmitz1
1Section of Interventional Cardiology, MedStar Washington Hospital Center, Washington, DC, USA.
Summary
The second-generation drug-eluting resorbable magnesium scaffold (RMS) shows promising results for coronary lesions. Long-term clinical data are needed to confirm its potential as an alternative to drug-eluting stents.
Area of Science:
- Cardiovascular medicine
- Biomaterials science
- Interventional cardiology
Background:
- The second-generation drug-eluting resorbable magnesium scaffold (RMS) has been utilized for coronary lesion treatment since October 2013.
- This innovative device is currently accessible in various global markets and undergoing post-marketing trials.
Purpose of the Study:
- To review the latest evidence on second-generation drug-eluting RMS.
- To compare its performance with other bioresorbable scaffolds.
- To discuss future perspectives and clinical case reports.
Main Methods:
- Literature review of clinical evidence and post-marketing trial data.
- Comparative analysis with existing bioresorbable scaffold technologies.
- Synthesis of clinical case reports and expert opinions.
Main Results:
- Favorable short-term outcomes have been reported following the implantation of second-generation drug-eluting RMS.
- The device is gaining clinical acceptance in Europe, South America, Asia, and Africa.
Conclusions:
- Second-generation drug-eluting RMS demonstrates potential as a future alternative to drug-eluting stents.
- Further long-term clinical outcome data are essential to fully establish the efficacy and safety of this novel scaffold.
